Vir Biotechnology, Inc. (VIR)

Vir Biotechnology, Inc. is a cutting-edge immunology company specializing in the development of innovative solutions to combat serious infectious diseases. Founded in 2016 by Robert Nelsen and headquartered in San Francisco, California, the company's mission is to integrate immunologic insights with cutting-edge technologies to treat and prevent severe viral infections. Vir has made significant strides in addressing global health challenges, particularly with its development of antibody therapies against COVID-19, hepatitis B, and influenza. The firm's collaborative approach includes partnerships with renowned organizations and research institutions to accelerate the delivery of groundbreaking therapies. As of recent reports, the company has been actively expanding its robust pipeline, which reflects its commitment to enhancing global health outcomes and maintaining sustainable revenue growth.